A Look at Xencor's (XNCR) Valuation After 60% Rally This Month

Xencor (XNCR) shares have moved nearly 60% higher over the past month, catching the attention of investors interested in biotechnology stocks with a turnaround story. Despite this rally, the stock remains well below year-ago levels. This creates a nuanced setup for those watching its next move.

See our latest analysis for Xencor.

Xencor’s recent surge comes after a tough run. Last month’s 59.7% share price return stands out sharply from the much weaker trend over the past year. Even with renewed momentum, the one-year total shareholder return is still down 32.2%. While short-term sentiment has improved, the long-term picture remains challenging.

Curious to see where other biotech breakthroughs are happening? Check out See the full list for free..

With Xencor trading far below its analyst price target despite improved short-term momentum, investors face a key question: is this a genuine buying opportunity, or has the market already factored in the company’s future prospects?

Most Popular Narrative: 42.2% Undervalued

Compared to the last close at $14.77, the most widely followed narrative assigns a much higher fair value. This significant gap sets up big expectations for future performance.

The robust and flexible XmAb platform allows for modular drug development and the creation of differentiated assets, expected to reduce development costs and timelines. This can directly benefit future operating margins and net profitability.

Read the complete narrative.

What if accelerating margins and modular innovation are behind this striking upside? The most important assumptions are not what you might expect. Want to uncover the numbers analysts are betting on to justify this high valuation? Discover exactly what could move this stock in the full breakdown.

Result: Fair Value of $25.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, setbacks such as delays in clinical trials or increased competition in the TL1A space could quickly change Xencor’s outlook and challenge growth assumptions.

Find out about the key risks to this Xencor narrative.

Another View: Multiples Put the Valuation in Perspective

While analyst narratives point toward strong future upside, looking at the company's price-to-sales ratio shows a different picture. Xencor trades at 7.2 times sales, which is richer than the fair ratio of 0.9 and above its closest peers at 5. This premium hints at elevated expectations and could mean investors are taking on more valuation risk than they realize. How much of the future growth is already priced in?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Xencor Narrative

If you see things differently or want to dig into the numbers on your own, it's easy to create your own story and reach your own conclusions in just a few minutes. Do it your way

A great starting point for your Xencor research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Unlock your next big opportunity by checking out top stocks in promising sectors. Don’t leave smart moves on the table. Be the first to spot what others miss.

• Spot massive price potential early and get ahead with these 3596 penny stocks with strong financials that are flashing strong financials and high growth signals.
• Kickstart your search for reliable passive income. Check out these 18 dividend stocks with yields > 3% and see who's delivering yields above 3% right now.
• Ride the momentum in fast-evolving healthcare technology by exploring these 33 healthcare AI stocks transforming patient outcomes and redefining what is possible in AI-driven care.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com